Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.

Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, DeBarber AE, Koop DR, Alkayed NJ.

Stroke. 2008 Jul;39(7):2073-8. doi: 10.1161/STROKEAHA.107.508325. Epub 2008 Mar 27.

2.

Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans.

Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Müller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M.

Stroke. 2008 May;39(5):1593-6. doi: 10.1161/STROKEAHA.107.502179. Epub 2008 Mar 6.

3.

Vascular cytochrome p450 enzymes: physiology and pathophysiology.

Fleming I.

Trends Cardiovasc Med. 2008 Jan;18(1):20-5. doi: 10.1016/j.tcm.2007.11.002. Review.

PMID:
18206805
4.

Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet.

Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD.

Hypertension. 2008 Feb;51(2):352-9. Epub 2007 Dec 24.

5.

The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis.

Segura MF, Sole C, Pascual M, Moubarak RS, Perez-Garcia MJ, Gozzelino R, Iglesias V, Badiola N, Bayascas JR, Llecha N, Rodriguez-Alvarez J, Soriano E, Yuste VJ, Comella JX.

J Neurosci. 2007 Oct 17;27(42):11228-41.

6.

The soluble epoxide hydrolase as a pharmaceutical target for hypertension.

Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD.

J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37. Review.

PMID:
17878749
8.

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD.

J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.

9.

Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.

Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ.

J Neurosci. 2007 Apr 25;27(17):4642-9.

10.

Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ.

J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40. Epub 2007 Apr 18.

11.

Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways.

Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, Lu ZY, Wang DW, Zeldin DC.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H142-51. Epub 2007 Feb 23.

12.

A new subtype classification of ischemic stroke based on treatment and etiologic mechanism.

Han SW, Kim SH, Lee JY, Chu CK, Yang JH, Shin HY, Nam HS, Lee BI, Heo JH.

Eur Neurol. 2007;57(2):96-102. Epub 2006 Dec 15.

PMID:
17179712
13.

Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.

Imig JD.

Cardiovasc Drug Rev. 2006 Summer;24(2):169-88. Review.

PMID:
16961727
14.

Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.

Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL.

Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2462-8. Epub 2006 Aug 17.

15.

Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function.

Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC.

Circ Res. 2006 Aug 18;99(4):442-50. Epub 2006 Jul 20.

16.

Development of a high-throughput screen for soluble epoxide hydrolase inhibition.

Wolf NM, Morisseau C, Jones PD, Hock B, Hammock BD.

Anal Biochem. 2006 Aug 1;355(1):71-80. Epub 2006 May 11.

17.
18.

Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature.

Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M.

Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H517-31. Epub 2006 Apr 14.

19.

Reduction of caspase-8 and -9 cleavage is associated with increased c-FLIP and increased binding of Apaf-1 and Hsp70 after neonatal hypoxic/ischemic injury in mice overexpressing Hsp70.

Matsumori Y, Northington FJ, Hong SM, Kayama T, Sheldon RA, Vexler ZS, Ferriero DM, Weinstein PR, Liu J.

Stroke. 2006 Feb;37(2):507-12. Epub 2006 Jan 5.

20.

The lifetime risk of stroke: estimates from the Framingham Study.

Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA.

Stroke. 2006 Feb;37(2):345-50. Epub 2006 Jan 5.

Supplemental Content

Support Center